Cannabidiol Ameliorates Blood-Brain Barrier Dysfunction and Inhibits Memory Astrocytes Activation in Mice With Sickness-Like Behaviors.

Chen Y.; Ma H.; Long Q.; Fang X.; Li X.; Xiao W.; Deng X.; Du F.; Tan Y.; Wang Y. et al. · CNS neuroscience & therapeutics · 2026

**Background & Methods** This study investigated cannabidiol (CBD) effects on depression-related pathology in mice with depressive-like behaviors using behavioral assessments and molecular analysis of blood-brain barrier (BBB) integrity and neuroinflammation. The research examined BBB dysfunction through measurement of tight junction proteins, aquaporin-4 (AQP4) expression, astrocyte activation, and neuroinflammatory markers following a single CBD dose administration. **Key Findings** • Mice with depressive-like phenotypes demonstrated reduced exploratory behavior, increased despair-like behavior, and BBB impairment characterized by downregulated tight junction proteins, decreased AQP4 expression, abnormal astrocyte activation, and elevated neuroinflammation. • A single dose of CBD ameliorated all pathological changes including restoring tight junction protein expression, normalizing AQP4 localization, reducing abnormal astrocyte activation, and decreasing neuroinflammatory markers. • CBD's therapeutic mechanism involved inhibition of memory astrocyte-associated secondary neuroinflammation, which mediated the alleviation of depressive-like behaviors and BBB dysfunction restoration. **Dosage & Administration** Not reported. The abstract indicates a "single CBD dose" was examined but specific dosing parameters, route of administration, and dosing schedules are not provided. **Safety & Adverse Effects** Not reported. The abstract does not discuss adverse effects, tolerability, or safety concerns associated with CBD administration in the study model. **Evidence Quality** This preclinical mouse study provides moderate evidence given its experimental design but has significant limitations. Primary limitations include: (1) use of animal models that may not fully translate to human depression pathophysiology; (2) examination of only a single CBD dose without dose-response analysis; (3) lack of comparison to standard antidepressant treatments; (4) unspecified details regarding animal numbers, statistical analysis, and blinding procedures; and (5) this being a review article rather than original research, potentially affecting methodological rigor. The identified mechanism linking BBB dysfunction and memory astrocyte activation to depression is novel and potentially valuable, but human clinical trials are necessary before clinical application. Results suggest CBD warrants further investigation as a potential therapeutic target for depression-related BBB dysfunction, though translational limitations must be considered.

More recent cannabis research